Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Niagen Bioscience, Inc. (NAGE) had Consolidated Net Income/Loss of $5.06M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$30.48M |
|
$5.06M |
|
$11.15M |
|
$19.33M |
|
$25.71M |
|
$4.77M |
|
$0.46M |
|
$5.23M |
|
$5.23M |
|
$5.06M |
|
$5.06M |
|
|
Consolidated Net Income/Loss |
$5.06M |
$5.06M |
|
$4.77M |
|
$4.97M |
|
77.81M |
|
83.23M |
|
$0.07 |
|
$0.06 |
|
| Balance Sheet Financials | |
$76.22M |
|
$1.66M |
|
$5.12M |
|
$81.34M |
|
$20.84M |
|
-- |
|
$5.16M |
|
$25.99M |
|
$55.34M |
|
$55.02M |
|
$55.34M |
|
78.43M |
|
| Cash Flow Statement Financials | |
$7.88M |
|
$-0.03M |
|
$3.10M |
|
$44.66M |
|
$55.62M |
|
$10.96M |
|
$1.07M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.66 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
63.42% |
|
15.66% |
|
15.66% |
|
-- |
|
17.16% |
|
16.61% |
|
$7.85M |
|
-- |
|
-- |
|
-- |
|
0.37 |
|
1.00 |
|
4.32 |
|
20.82 |
|
9.15% |
|
9.20% |
|
6.22% |
|
9.15% |
|
$0.71 |
|
$0.09 |
|
$0.09 |
|